XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma

This article was originally published here

Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has

The post XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply